文献速递心力衰竭与心肌病心律失常

植入式心律转复除颤器与非缺血性心肌病患者的死亡率:一项更新的荟萃分析

Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis.
PubMed 文献 · Heart · 2017-08-05

该荟萃分析纳入6项随机对照试验共1715例非缺血性心肌病患者,评估植入式心律转复除颤器(ICD)对死亡率的影响。结果显示ICD治疗降低全因死亡率(HR 0.78,95%CI 0.66-0.92)、心血管死亡率(RR 0.77,95%CI 0.60-0.98)和心源性猝死(RR 0.45,95%CI 0.29-0.70),且获益不受胺碘酮、随访时长、β受体阻滞剂等因素影响。

要点

  • ICD降低非缺血性心肌病患者全因死亡率(HR 0.78)。
  • ICD降低心血管死亡率(RR 0.77)和心源性猝死(RR 0.45)。
  • 获益不受胺碘酮、随访时长、β受体阻滞剂等影响。

核心结论

  • 对于非缺血性心肌病患者,一级预防性ICD治疗可降低全因死亡率、心血管死亡率和心源性猝死。

研究设计与样本

  • 纳入6项随机对照试验,共1715例非缺血性心肌病患者,发生421例死亡。

主要发现

  • ICD治疗与全因死亡率降低相关(HR 0.78,95%CI 0.66-0.92,I2=0%,风险差4.7%,高质量证据)。
  • ICD治疗与心血管死亡率降低相关(RR 0.77,95%CI 0.60-0.98,I2=39%,风险差3.3%,高质量证据)。
  • ICD治疗与心源性猝死降低相关(RR 0.45,95%CI 0.29-0.70,I2=0%,风险差4.1%,高质量证据)。
  • ICD的获益不受对照组使用胺碘酮、随访时长、使用β受体阻滞剂和ACE抑制剂/血管紧张素受体阻滞剂或心脏再同步治疗的影响。

临床怎么用

  • 对于非缺血性心肌病患者,可考虑一级预防性ICD治疗以降低死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The benefit of implantable cardiac defibrillator (ICD) in symptomatic patients with systolic dysfunction and non-ischaemic cardiomyopathy remains controversial. We conducted a systematic review and meta-analysis to determine the effect of ICD in patients with non-ischaemic cardiomyopathy on (1) all-cause mortality, (2) cardiovascular mortality and (3) sudden cardiac death. METHODS: We searched citations in meta-analyses published until 2012, and in MEDLINE, Embase, PubMed and Cochrane databases from 2012 to October 2016. We included randomised controlled trials (RCTs) evaluating the effect of ICD therapy on all-cause and cardiovascular mortality and sudden cardiac death in patients with non-ischaemic cardiomyopathy. Independent reviewers evaluated study eligibility, abstracted data and assessed risk of bias in duplicate. We used random-effect models to meta-analyse relative risks (RR) and hazard ratios (HR) across studies, the Grades of Recommendation, Assessment, Development, and Evaluation system to quantify absolute effects and quality of evidence, and I2 to evaluate heterogeneity. RESULTS: We identified six RCTs including 1715 patients experiencing 421 deaths. ICD therapy was associated with reduced overall mortality (HR 0.78, 95% CI 0.66 to 0.92, I2 = 0%, risk difference 4.7%, high quality), cardiovascular mortality (RR 0.77, 95% CI 0.60 to 0.98, I2 = 39%, risk difference 3.3%, high quality) and sudden cardiac death (RR 0.45, 95% CI 0.29 to 0.70, I2 = 0%, risk difference 4.1%, high quality). The benefit of ICD was not influenced by the use of amiodarone in the comparison group, the duration of follow-up, by use of β-blockers and ACE inhibitors/angiotensin receptor blocker or cardiac resynchronisation therapy. CONCLUSION: Primary prevention ICD therapy reduces all-cause and cardiovascular mortality and sudden cardiac death in patients with non-ischaemic cardiomyopathy.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Alba AC, Foroutan F, Duero Posada J, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2017. PMID: 28780582. doi:10.1136/heartjnl-2017-311430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。